JP2025509995A5 - - Google Patents
Info
- Publication number
- JP2025509995A5 JP2025509995A5 JP2024556197A JP2024556197A JP2025509995A5 JP 2025509995 A5 JP2025509995 A5 JP 2025509995A5 JP 2024556197 A JP2024556197 A JP 2024556197A JP 2024556197 A JP2024556197 A JP 2024556197A JP 2025509995 A5 JP2025509995 A5 JP 2025509995A5
- Authority
- JP
- Japan
- Prior art keywords
- group
- groups
- heterocyclyl
- alkyl
- cycloalkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210330007 | 2022-03-28 | ||
| CN202210330007.4 | 2022-03-28 | ||
| CN202210944231.2 | 2022-08-05 | ||
| CN202210944231 | 2022-08-05 | ||
| CN202211255163.5 | 2022-10-13 | ||
| CN202211255163 | 2022-10-13 | ||
| PCT/CN2023/084265 WO2023185793A1 (zh) | 2022-03-28 | 2023-03-28 | 含氮杂环类化合物、其制备方法及其在医药上的应用 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2025509995A JP2025509995A (ja) | 2025-04-11 |
| JP2025509995A5 true JP2025509995A5 (cg-RX-API-DMAC7.html) | 2026-04-06 |
Family
ID=88199144
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024556197A Pending JP2025509995A (ja) | 2022-03-28 | 2023-03-28 | 含窒素複素環系化合物、その調製方法及びその医薬的使用 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20250206760A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4501925A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2025509995A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20240167844A (cg-RX-API-DMAC7.html) |
| CN (1) | CN118715216A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2023243776A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3253847A1 (cg-RX-API-DMAC7.html) |
| MX (1) | MX2024011705A (cg-RX-API-DMAC7.html) |
| TW (1) | TW202345816A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2023185793A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW202309022A (zh) | 2021-04-13 | 2023-03-01 | 美商努法倫特公司 | 用於治療具egfr突變之癌症之胺基取代雜環 |
| EP4786473A1 (en) * | 2023-09-27 | 2026-08-05 | Jiangsu Hengrui Pharmaceuticals Co., Ltd. | Pharmaceutically acceptable salt and crystalline form of quinazoline derivative, and use thereof |
| TW202530232A (zh) * | 2023-09-27 | 2025-08-01 | 大陸商江蘇恒瑞醫藥股份有限公司 | 喹唑啉衍生物的結晶形式及其製備方法 |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1437594A (zh) * | 2000-06-22 | 2003-08-20 | 辉瑞产品公司 | 用于治疗异常细胞生长的取代的双环衍生物 |
| JP4828421B2 (ja) * | 2003-08-14 | 2011-11-30 | アレイ バイオファーマ、インコーポレイテッド | 受容体チロシンキナーゼ阻害剤としてのキナゾリン誘導体 |
| DE602006021645D1 (de) * | 2005-11-15 | 2011-06-09 | Array Biopharma Inc | Verfahren und Zwischenverbindungen zur Herstellung von N4-Phenyl-Quinazolin-4-Amin Derivaten |
| AR092289A1 (es) * | 2011-11-14 | 2015-04-15 | Sunshine Lake Pharma Co Ltd | Derivados de aminoquinazolina y sus sales y metodos de uso |
| CN104744446B (zh) * | 2013-12-30 | 2019-06-25 | 广东东阳光药业有限公司 | 杂芳化合物及其在药物中的应用 |
| CN115057861A (zh) | 2016-03-01 | 2022-09-16 | 上海医药集团股份有限公司 | 一种含氮杂环化合物、制备方法、中间体、组合物和应用 |
| TWI811358B (zh) * | 2018-05-08 | 2023-08-11 | 大陸商迪哲(江蘇)醫藥股份有限公司 | ErbB受體抑制劑 |
| HRP20240293T1 (hr) * | 2018-09-18 | 2024-05-24 | F. Hoffmann - La Roche Ag | Derivati kinazolina kao protutumorska sredstva |
| US20230126204A1 (en) | 2020-02-03 | 2023-04-27 | Boehringer Ingelheim International Gmbh | [1,3]DIAZINO[5,4-d]PYRIMIDINES AS HER2 INHIBITORS |
| CN115052881B (zh) | 2020-02-03 | 2024-07-09 | 勃林格殷格翰国际有限公司 | 作为HER2抑制剂的[1,3]二嗪并[5,4-d]嘧啶 |
| CA3175102A1 (en) * | 2020-03-13 | 2021-09-16 | Suzhou Zanrong Pharma Ltd. | Erbb receptor inhibitors as anti-tumor agents |
| US11608343B2 (en) | 2020-04-24 | 2023-03-21 | Boehringer Ingelheim International Gmbh | Substituted pyrimido[5,4-d]pyrimidines as HER2 inhibitors |
| WO2021231400A1 (en) | 2020-05-12 | 2021-11-18 | Accutar Biotechnology, Inc. | Bis-aryl ethers containing n-acyl azetidine as egfr/her2 inhibitors |
| CN115697994B (zh) | 2020-06-10 | 2024-08-13 | 江苏恒瑞医药股份有限公司 | 稠合喹唑啉类衍生物、其制备方法及其在医药上的应用 |
| TW202214641A (zh) | 2020-06-30 | 2022-04-16 | 美商艾瑞生藥股份有限公司 | Her2突變抑制劑 |
| US20240398805A1 (en) * | 2021-02-05 | 2024-12-05 | Accutar Biotechnology Inc. | Quinazoline derived compounds as egfr inhibitors and their uses thereof |
| EP4476211A4 (en) * | 2022-02-09 | 2026-02-25 | Enliven Inc | ACYLIC HETEROCYCLIC QUINAZOLINE DERIVATIVES USED AS ERBB2 INHIBITORS |
-
2023
- 2023-03-28 US US18/851,679 patent/US20250206760A1/en active Pending
- 2023-03-28 CN CN202380022951.6A patent/CN118715216A/zh active Pending
- 2023-03-28 WO PCT/CN2023/084265 patent/WO2023185793A1/zh not_active Ceased
- 2023-03-28 KR KR1020247034812A patent/KR20240167844A/ko active Pending
- 2023-03-28 TW TW112111777A patent/TW202345816A/zh unknown
- 2023-03-28 AU AU2023243776A patent/AU2023243776A1/en active Pending
- 2023-03-28 CA CA3253847A patent/CA3253847A1/en active Pending
- 2023-03-28 EP EP23778158.8A patent/EP4501925A4/en active Pending
- 2023-03-28 JP JP2024556197A patent/JP2025509995A/ja active Pending
-
2024
- 2024-09-24 MX MX2024011705A patent/MX2024011705A/es unknown